Bon Natural Life vs MediWound
BON and MDWD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BON and MDWD compare
MediWound scores higher on the StockData Score (2 against 0 for Bon Natural Life), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BON | MDWD |
|---|---|---|
| Size and price | ||
| Share price | $1.10 | $12.97 |
| Change, 1 year | −42.4% | −30.0% |
| Change, 5 years | −99.9% | −35.4% |
| Beta (5Y) | 0.94 | 0.90 |
| Employees | 96 | 35 |
| StockData Score | ||
| Total score | 0 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | – | −16.1% |
| Revenue growth, 5Y average | – | −4.9% |
| Profitability | ||
| Gross margin | – | 19.2% |
| Operating margin | – | −149% |
| FCF margin | – | −128% |
| Financial health | ||
| Interest coverage | – | −10.3× |
| Current ratio | – | 2.32 |
| Ownership | ||
| Held by institutions | – | 45.3% |
| Held by insiders | 1.0% | 23.4% |
| Insider net buying, 12 months | – | $60.6K |
| Short interest, % of float | 0.17% | 18.2% |
Go deeper
- BON stock overview
- BON income statement
- BON valuation and score
- MDWD stock overview
- MDWD income statement
- MDWD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.